Cover Image
市場調查報告書

腎細胞癌:全球藥物市場預測、開發平台分析 (∼2021年)

Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021

出版商 iGate Research Pvt Ltd 商品編碼 360473
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
腎細胞癌:全球藥物市場預測、開發平台分析 (∼2021年) Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021
出版日期: 2016年05月16日 內容資訊: 英文 148 Pages
簡介

全球腎細胞癌治療藥的市場預計2021年成長到超過43億美元的規模。文明病的風險擴大和腎細胞癌的盛行率擴大,老年人口的增加,最新的影像技術的快速診斷等要素促進該市場的成長。

本報告提供全球腎細胞癌治療藥的市場調查,腎細胞癌的疾病概要及流行病學,全球及主要國家的發病診斷數及5年患病人數的變化與預測,腎細胞癌治療藥概要,銷售額及市場佔有率的變化與預測,領導品牌藥的產品簡介和銷售額規模的變化與預測,開發平台分析,市場促進因素、阻礙要素分析等彙整資料。

第1章 摘要整理

第2章 腎細胞癌 (RCC):疾病概要

  • 病因、病理生理學
  • 癌症分期
  • 症狀
  • 預後
  • 潛在的生物標記
    • 血清中分子生物標記
    • 尿中分子生物標記

第3章 腎細胞癌 (RCC):流行病學

  • 疾病的背景
  • 風險因素、並存症
  • 發病率

第4章 全球腎細胞癌:流行病學的預測

  • 全球發病診斷數的預測 (20歲以上)
  • 全球5年患病人數的預測 (20歲以上)

第5章 全球腎細胞癌 (RCC):發病診斷數、5年患病人數的預測 (20歲以上)

  • 美國
  • 義大利
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 日本
  • 中國

第6章 全球腎細胞癌:藥物市場分析、預測

  • 藥物市場分析、預測
  • 藥物市場佔有率與預測

第7章 領導品牌藥的產品簡介、銷售額

  • Sutent (Sunitinib)
    • 產品簡介
    • 全球銷售額、預測
  • Nexavar (Sorafenib)
    • 產品簡介
    • 全球銷售額、預測
  • Votrient (Pazopanib)
    • 產品簡介
    • 全球銷售額、預測
  • Avastin (Bevacizumab)
    • 產品簡介
    • 全球銷售額、預測
  • Afinitor (Everolimus)
    • 產品簡介
    • 全球銷售額、預測
  • Inlyta (Axitinib)
    • 產品簡介
    • 全球銷售額、預測
  • Torisel (Temsirolimus)
    • 產品簡介
    • 全球銷售額、預測
  • Proleukin (Aldesleukin)
    • 產品簡介
    • 全球銷售額、預測
  • Opdivo (Nivolumab):產品簡介
  • Tarceva (Erlotinib):產品簡介
  • Interferon-alfa:產品簡介

第8章 全球腎細胞癌治療藥市場:各企業的開發平台分析

  • Merck & Co., Inc.
  • Exelixis Inc
  • Argus Therapeutics, Inc.
  • Bristol-Myers Squibb
  • Genentech/Roche
  • Immatics Biotechnologies
  • AVEO Oncology
  • Eisai
  • Acceleron
  • Rexahn Pharmaceuticals
  • Bionomics
  • Cerulean Pharma Inc.
  • Celldex Therapeutics
  • TVAX Biomedical
  • TRACON Pharmaceuticals
  • Eli Lilly
  • AstraZeneca

第9章 全球腎細胞癌治療藥市場:成長推進因素

  • 腎細胞癌的發病率的增加
  • 老年人口的增加
  • 強力的開發平台候補藥
  • 新的治療選擇

第10章 全球腎細胞癌治療藥市場:阻礙成長要素

  • 品牌藥的高價格性
  • 學名藥的選擇

圖表

目錄

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma. The major driving factors for the renal cell carcinoma drugs market are increasing risk of lifestyle induced diseases, growing prevalence of renal cell carcinoma, increasing geriatric population base and quick diagnosis with modern imaging techniques.

The major drugs used for the treatment of renal cell carcinoma include Sutent, Nexavar, Votrient, Avastin and Inyta amongst others. Sutent accounts for largest share of the global renal cell carcinoma drugs market in 2015, while, Votrient is projected to witness the strongest growth during the forecasting period. The most recent drugs approved for the treatment of renal cell carcinoma is Bristol-Myers Squibb's Opdivo. Moreover, there are many pipeline drugs in various phases of clinical trials, which will fuel the growth of renal cell carcinoma drugs market.

iGATE RESEARCH report entitled “Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021” provides a comprehensive analysis of the fast-evolving high growth renal cell carcinoma therapeutics market. This 148 Page report with 58 Figures and 4 Tables has been analyzed from 7 viewpoints:

  • 1. Renal Cell Carcinoma (RCC) - Disease Overview
  • 2. Renal Cell Carcinoma (RCC) - Epidemiology
  • 3. Global Renal Cell Carcinoma - Diagnosed Incident Cases to 2023 (8 Countries Covered)
  • 4. Global Renal Cell Carcinoma - Five-Year Diagnosed Prevalent Cases to 2023 (8 Countries Covered)
  • 5. Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)
  • 6. Global Renal Cell Carcinoma Drugs - Pipeline Analysis (18 Drugs Covered)
  • 7. Global Renal Cell Carcinoma Drugs - Market Drivers and Restraints

Global Renal Cell Carcinoma - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases to 2023 (8 Countries Covered)

  • 1. United States
  • 2. Italy
  • 3. Germany
  • 4. France
  • 5. United Kingdom
  • 6. Spain
  • 7. Japan
  • 8. China

Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)

  • 1. Sutent (Sunitinib)
  • 2. Nexavar (Sorafenib)
  • 3. Votrient (Pazopanib)
  • 4. Avastin (Bevacizumab)
  • 5. Afinitor (Everolimus)
  • 6. Inlyta (Axitinib)
  • 7. Torisel (Temsirolimus)
  • 8. Proleukin (Aldesleukin)
  • 9. Opdivo (Nivolumab) - Product Profile
  • 10. Tarceva (Erlotinib) - Product Profile
  • 11. Interferon-alfa - Product Profile

Global Renal Cell Carcinoma Drugs - Pipeline Analysis (17 Companies Drugs Covered)

  • 1. Merck & Co., Inc.
  • 2. Exelixis Inc
  • 3. Argus Therapeutics, Inc.
  • 4. Bristol-Myers Squibb
  • 5. Genentech/Roche
  • 6. Immatics Biotechnologies
  • 7. AVEO Oncology
  • 8. Eisai
  • 9. Acceleron
  • 10. Rexahn Pharmaceuticals
  • 11. Bionomics
  • 12. Cerulean Pharma Inc
  • 13. Celldex Therapeutics
  • 14. TVAX Biomedical
  • 15. TRACON Pharmaceuticals
  • 16. Eli Lilly
  • 17. AstraZeneca

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Renal Cell Carcinoma (RCC) - Disease Overview

  • 2.1 Etiology and Pathophysiology
    • 2.1.1 Etiology
    • 2.1.2 Pathophysiology
  • 2.2 Renal Cell Carcinoma Staging
  • 2.3 Symptoms
  • 2.4 Prognosis
  • 2.5 Potential Biomarkers
    • 2.5.1 Molecular Markers in Serum
    • 2.5.2 Molecular Markers in Urine

3. Renal Cell Carcinoma (RCC) - Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Incidence

4. Global Renal Cell Carcinoma - Epidemiological Forecast (2012 - 2023)

  • 4.1 Renal Cell Carcinoma - Global Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
  • 4.2 Renal Cell Carcinoma - Global Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast

5. Global Renal Cell Carcinoma (RCC) - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (2012 - 2023)

  • 5.1 United States RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.1.1 RCC - United States Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.1.2 RCC - United States Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.2 Italy RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.2.1 RCC - Italy Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.2.2 RCC - Italy Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.3 Germany RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.3.1 RCC - Germany Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.3.2 RCC - Germany Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.4 France RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.4.1 RCC - France Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.4.2 RCC - France Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.5 United Kingdom RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.5.1 RCC - United Kingdom Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.5.2 RCC - United Kingdom Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.6 Spain RCC- Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.6.1 RCC - Spain Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.6.2 RCC - Spain Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.7 Japan RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.7.1 RCC - Japan Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.7.2 RCC - Japan Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast
  • 5.8 China RCC - Diagnosed Incident Cases and Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years)
    • 5.8.1 RCC - China Diagnosed Incident Cases (Ages ge;20 Years) and Forecast
    • 5.8.2 RCC - China Five-Year Diagnosed Prevalent Cases (Ages ge;20 Years) and Forecast

6. Global Renal Cell Carcinoma - Drugs Market Analysis (2012 - 2021)

  • 6.1 Global Renal Cell Carcinoma - Drugs Market and Forecast
  • 6.2 Global Renal Cell Carcinoma - Drugs Market Share and Forecast

7. Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales

  • 7.1 Sutent (Sunitinib) - Product Profile and Sales
    • 7.1.1 Sutent (Sunitinib) - Product Profile
    • 7.1.2 Sutent (Sunitinib) - Global Sales and Forecast (2012 - 2021)
  • 7.2 Nexavar (Sorafenib) - Product Profile and Sales
    • 7.2.1 Nexavar (Sorafenib) - Product Profile
    • 7.2.2 Nexavar (Sorafenib) - Global Sales and Forecast (2012 - 2021)
  • 7.3 Votrient (Pazopanib) - Product Profile and Sales
    • 7.3.1 Votrient (Pazopanib) - Product Profile
    • 7.3.2 Votrient (Pazopanib) - Global Sales and Forecast (2012 - 2021)
  • 7.4 Avastin (Bevacizumab) - Product Profile and Sales
    • 7.4.1 Avastin (Bevacizumab) - Product Profile
    • 7.4.2 Avastin (Bevacizumab) - Global Sales and Forecast (2012 - 2021)
  • 7.5 Afinitor (Everolimus) - Product Profile and Sales
    • 7.5.1 Afinitor (Everolimus) - Product Profile
    • 7.5.2 Afinitor (Everolimus) - Global Sales and Forecast (2012 - 2021)
  • 7.6 Inlyta (Axitinib) - Product Profile and Sales
    • 7.6.1 Inlyta (Axitinib) - Product Profile
    • 7.6.2 Inlyta (Axitinib) - Global Sales and Forecast (2012 - 2021)
  • 7.7 Torisel (Temsirolimus) - Product Profile and Sales
    • 7.7.1 Torisel (Temsirolimus) - Product Profile
    • 7.7.2 Torisel (Temsirolimus) - Global Sales and Forecast (2012 - 2021)
  • 7.8 Proleukin (Aldesleukin) - Product Profile and Sales
    • 7.8.1 Proleukin (Aldesleukin) - Product Profile
    • 7.8.2 Proleukin (Aldesleukin) - Global Sales and Forecast (2012 - 2021)
  • 7.9 Opdivo (Nivolumab) - Product Profile
  • 7.10 Tarceva (Erlotinib) - Product Profile
  • 7.11 Interferon-alfa - Product Profile

8. Global Renal Cell Carcinoma Drugs Market - Company Wise Pipeline Analysis

  • 8.1 Merck & Co., Inc.
  • 8.2 Merck & Co., Inc.
  • 8.3 Exelixis Inc
  • 8.4 Argus Therapeutics, Inc.
  • 8.5 Bristol-Myers Squibb
  • 8.6 Genentech/Roche
  • 8.7 Immatics Biotechnologies
  • 8.8 AVEO Oncology
  • 8.9 Eisai
  • 8.10 Acceleron
  • 8.11 Rexahn Pharmaceuticals
  • 8.12 Bionomics
  • 8.13 Cerulean Pharma Inc.
  • 8.14 Celldex Therapeutics
  • 8.15 TVAX Biomedical
  • 8.16 TRACON Pharmaceuticals
  • 8.17 Eli Lilly
  • 8.18 AstraZeneca

9. Global Renal Cell Carcinoma Drugs - Market Drivers

  • 9.1 Rising Incidence of Renal Cell Carcinoma Expected to Fuel Market Growth
  • 9.2 Increasing Elderly Population Likely to Drive Renal Cell Carcinoma Drugs Market
  • 9.3 Strong Pipeline Candidates is Expected to Drive Market Growth
  • 9.4 Novel Treatment Option for Renal Cell Carcinoma

10. Global Renal Cell Carcinoma Drugs - Market Restraints

  • 10.1 High Prices of Branded Renal Cell Carcinoma Drugs
  • 10.2 Increasing Preference for Generic Drug Variants Would Hamper the Market

List of Figures:

  • Figure 4-1: Global - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 4-2: Global - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 4-3: Global - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 4-4: Global - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-1: United States - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-2: United States - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-3: United States - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-4: United States - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-5: Italy - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-6: Italy - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-7: Italy - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-8: Italy - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-9: Germany - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-10: Germany - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-11: Germany - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-12: Germany - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-13: France - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-14: France - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-15: France - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-16: France - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-17: United Kingdom - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-18: United Kingdom - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-19: United Kingdom - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-20: United Kingdom - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-21: Spain - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-22: Spain - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-23: Spain - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-24: Spain - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-25: Japan - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-26: Japan - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-27: Japan - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-28: Japan - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-29: China - Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-30: China - Forecast for Diagnosed Incident Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 5-31: China - Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2012 - 2015
  • Figure 5-32: China - Forecast for Five-Year Diagnosed Prevalent Cases of RCC, Ages ge;20 Years (Number), 2016 - 2023
  • Figure 6-1: Global - Renal Cell Carcinoma Drugs Market (Million US$), 2012 - 2015
  • Figure 6-2: Global - Forecast for Renal Cell Carcinoma Drugs Market (Million US$), 2016 - 2021
  • Figure 6-3: Global - Renal Cell Carcinoma Drugs Market Share (Percent), 2012 - 2015
  • Figure 6-4: Global - Forecast for Renal Cell Carcinoma Drugs Market Share (Percent), 2016 - 2021
  • Figure 7-1: Sutent (Sunitinib) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-2: Sutent (Sunitinib) - Forecast for Global Sales (Million US$), 2016 - 20121
  • Figure 7-3: Nexavar (Sorafenib) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-4: Nexavar (Sorafenib) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 7-5: Votrient (Pazopanib) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-6: Votrient (Pazopanib) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 7-7: Avastin (Bevacizumab) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-8: Avastin (Bevacizumab) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 7-9: Afinitor (Everolimus) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-10: Afinitor (Everolimus) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 7-11: Inlyta (Axitinib) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-12: Inlyta (Axitinib) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 7-13: Torisel (Temsirolimus) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-14: Torisel (Temsirolimus) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 7-15: Proleukin (Aldesleukin) - Global Sales (Million US$), 2012 - 2015
  • Figure 7-16: Proleukin (Aldesleukin) - Forecast for Global Sales (Million US$), 2016 - 2021
  • Figure 9-1: World Population - Over 60 Years of Age (Thousand), 2012 - 2015
  • Figure 9-2: World Population - Forecast for Over 60 Years of Age (Thousand), 2016 - 2021

List of Tables:

  • Table 2-1: Percentage of People Surviving the Cancer (Percent)
  • Table 2-2: Potential Serum Biomarkers in Renal Cell Carcinoma
  • Table 2-3: Potential Urinary Biomarkers in Renal Cell Carcinoma
  • Table 9-1: Renal Cell Carcinoma - List of Drugs in the Pipeline (February 2016)
Back to Top